Precision Medicine in Interventional Cardiology: Implications for Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

Mattía Galli(Maria Cecilia Hospital), Dominick J. Angiolillo(Jacksonville University), Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Francesco Franchi(Florida College), Fabiana Rollini(Florida College)
Pharmacogenomics
August 1, 2022
10.2217/pgs-2022-0057
Cited by 48

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|877
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
|Thrombosis and Haemostasis|2020|334